Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB-MMAE-6
- Development stage
- Preclinical
- Lead developer
- Precision Biologics
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PB-MMAE-6 is an investigational antibody-drug conjugate (ADC) developed by Precision Biologics. It consists of the monoclonal antibody PB-223 conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) via a cysteine-based, protease-cleavable mc-vc-PABc linker. The drug-to-antibody ratio (DAR) for this ADC is 4.15, indicating a high payload loading per antibody molecule. PB-MMAE-6 targets cancer cells expressing core 2 O-glycans and has demonstrated strong binding affinity and potent cytotoxicity against OV-90 human ovarian cancer cells in vitro, with 80% cell death observed five days post-treatment. While most in vivo efficacy and safety data are available for the closely related clone PB-MMAE-5, all three ADCs (PB-MMAE-2, -5, -6) share similar binding and killing profiles in preclinical models[3]. MMAE acts as a microtubule inhibitor that blocks tubulin polymerization, leading to cell cycle arrest at G2/M phase and subsequent apoptosis[3][5]. The linker ensures stability in circulation but allows release of MMAE inside target cells following endocytosis.
- Brand names
- PB-MMAE-6PB-MMAE6PB-MMAE 6
- Other names
- PB-MMAE-6PB-MMAE6PB-MMAE 6
02
Targets
Core 2 O-glycan-expressing tumor cell surface antigenTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on PB-MMAE-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PB-MMAE-6.